CalciMedica, Inc. (NASDAQ: CALC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
CalciMedica Reports Third Quarter 2024 Financial Results and Provides Clinical & Corporate Updates
CalciMedica Strengthens Leadership Team with Appointment of Stephen Bardin as Chief Financial Officer
CalciMedica, Inc. (NASDAQ: CALC) had its price target lowered by analysts at HC Wainwright from $20.00 to $16.00. They now have a "buy" rating on the stock.
CalciMedica Announces Pricing of Public Offering of Common Stock